Earlier this month, the first LSIPR roundtable discussion took place in a London hotel, chaired by managing editor Martin Essex, with six invited experts and deputy editor Ed Conlon taking part. We’ll be publishing a special report on the event but, to whet your appetite, here’s how the discussion began—with a lively debate on the USPTO’s guidelines on patent-eligible subject matter in the wake of the Myriad and Mayo court decisions.
HemoShear creates systems for predicting human responses to drugs by applying its proprietary technology to human cells in the lab to make them behave the way they would in vivo. LSIPR found out about its strategy for protecting and developing its technologies.
The PharmaSea project is working to make viable drug candidates of novel compounds found under the sea. LSIPR discovers how the EU-funded initiative does it.
China, Japan and South Korea are three of the most developed markets in the world for pharmaceuticals but they still offer a wealth of opportunities for both innovators and generic drug companies. LSIPR looks at the protection available for those seeking to do business there.
There is no uniform interpretation of the scope of the Bolar exemption in Europe, but a CJEU opinion harmonising the issue may be on the way, says Rafal Witek.
The effect of obviousness-type double patenting on patent term extension and patent term adjustment in the biotech and pharma industry needs careful consideration, as Gaby L. Longsworth and Eric K. Steffe report.
Arguments over the term of the patents granted are at the heart of the Copaxone conflict, says Archana Shanker.
A new referral to the CJEU should shed light on the extent of the so-called Bolar exemption in Europe, says Bernd Allekotte.
Several of the world’s 10 top-selling drugs lose exclusivity this year. LSIPR takes a look at the products, their major competitors, and their manufacturers’ strategies for keeping a grasp of market share.
The CJEU has delivered its judgment in three SPC cases, in an attempt to address fundamental issues in the SPC Regulation, as well as uncertainties arising from earlier rulings. Although questions have been answered, others have been raised, say David Carling and Michael Pears.